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Hydroxyurea (HU) has been used clinically to reduce the frequency
of painful crisis and the need for blood transfusion in sickle cell
disease (SCD) patients. However, the mechanisms underlying such
beneficial effects of HU treatment are still not fully understood.
Studies have indicated a weak correlation between clinical outcome
and molecular markers, and the scientific quest to develop compan-
ion biophysical markers have mostly targeted studies of blood
properties under hypoxia. Using a common-path interferometric
technique, wemeasure biomechanical andmorphological properties
of individual red blood cells in SCD patients as a function of cell
density, and investigate the correlation of these biophysical prop-
erties with drug intake as well as other clinically measured param-
eters. Our results show that patient-specific HU effects on the
cellular biophysical properties are detectable at normoxia, and that
these properties are strongly correlated with the clinically measured
mean cellular volume rather than fetal hemoglobin level.
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Sickle cell disease (SCD), an autosomal recessive disease,resulted in 176,000 deaths worldwide in 2013 (1). In SCD, a
point mutation occurs in the gene responsible for the production
of β-chain in hemoglobin (Hb), the main protein in red blood
cells (RBCs) that is responsible for oxygen transport (2). This
mutation changes the hydrophilic glutamic acid to a hydrophobic
valine amino acid residue in the β-globin chain gene, giving rise
to hemoglobin S (HbS), a variant form of Hb. Under low-oxygen
(hypoxic) conditions, the hydrophobic residues within cytosol
associate with one another to form polymerized fibers that alter
the RBC shape (3). Although these fibers “melt” when cells ex-
perience normal oxygen (normoxic) environments, irreversible
damage results from repeated exposure to alternating low-oxygen
and normoxic environments, thereby giving rise to stiffer sickle
RBCs (sRBCs). These sRBCs adversely affect blood flow and are
associated with vessel occlusion, poor oxygen transport, and he-
molysis (4). The ensuing painful episodes of vasoocclusive crises
can additionally cause tissue injury that is another pathological
effect associated with the disease (3, 5).
Despite the wealth of information known about SCD, optimal
treatments do not exist. Patients suffering from SCD can amelio-
rate their disease severity with blood transfusions, and through
treatment involving hydroxyurea (HU), which is the only drug for
SCD approved by US Food and Drug Administration (FDA), or
by recourse to pain management drugs such as opiates. Studies
have shown that intake of HU, among other effects, increases the
fraction of fetal Hb (HbF) in the RBCs (6). The corresponding
reduction in the concentration of HbS delays polymerization of
HbS upon deoxygenation, thereby reducing the probability of
sickling and minimizing the resultant deleterious consequences (7).
There have been other therapeutic agents that have been shown to
increase production of HbF as well; however, none of them is
currently approved by the FDA (8, 9). Other effects of HU ad-
ministration in SCD patients on RBCs include larger cell volumes
(10), increased antioxidant activity (11), reduced adhesiveness
(12–14), and greater filterability (15). Mechanisms underlying
these and other beneficial effects of the drug affecting leukocytes
and the endothelium (16–18) have not been fully elucidated.
Nevertheless, the consensus for management of SCD care is
administration of HU due to its success in both adult and chil-
dren populations (19–23). It must be noted, however, that there
are patient populations who are unresponsive to HU treatment
(24). Identifying patient-specific markers that predict HU ef-
fectiveness would, therefore, greatly improve SCD care.
Clinical studies have demonstrated that there exists a high
degree of diversity in response to HU treatment among those
homozygous for HbS even among identical molecular signatures
(25). Multiple studies have indicated either a lack of, or weak,
correlation between clinical outcome and molecular markers
such as volume fraction of the HbS in the blood (25–28). Al-
though biochemical markers alone cannot fully describe disease
severity or effectiveness of treatment, biophysical markers may
provide a complementary pathway to gaining insight into disease
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pathophysiology (29). As the primary consequence of mutation in
the β-globin chain gene is formation of HbS fibers within the cy-
tosol under low-oxygen environment, biophysical studies have been
mainly focused on identifying biomarkers under hypoxic condition.
Measuring rheological properties of the blood under hypoxia has
been suggested as one such indicator of the propensity for vaso-
occlusive crisis in sickle patients (29, 30). Here, we hypothesize that
biophysical properties of individual RBCs of sickle patients at
normoxia, including morphology and biomechanical properties,
could better characterize physiological changes due to HU treat-
ment than molecular-level markers. Our hypothesis is based on the
assumption that normoxic biophysical properties of red cells are
affected by what they have undergone while circulating in blood of
the patients such as repeated cycles of blood oxygenation and
deoxygenation. We measure these biophysical properties using a
common-path interferometric technique comparing patients who
are on and off HU treatment. Comparison between the biophysical
properties of RBCs and clinically measured parameters for SCD
patients indicates that biomechanical properties and morphology
at the individual-cell level can provide insights into the effective-
ness of HU treatment, possibly leading to a better understanding
of the mechanism underlying the drug.
Results
Density-Dependent Biophysical Properties of Individual Red Cells.
Common-path interferometric microscopy enables noninvasive
and quantitative measurements of the morphological features of
the biological samples at the nanometer scale (31). These mi-
croscopes have previously been used to study morphological and
biomechanical properties of the RBCs (32, 33). Fig. 1 shows the
range of biophysical properties that can be assessed by measuring
the morphology of RBCs and monitoring this morphology over
time at the millisecond timescale. However, such measurements
in transmission-type interferometers are affected by the re-
fractive index (RI) differences of individual cells, and an average
value is typically assumed for the entire cell population under
investigation. The RI of RBCs is directly related to the con-
centration of proteins in cytosol, which, in the case of RBCs, is
composed mainly of Hb. Accounting for such variations is vital
in the case of RBCs of SCD patients, in particular, because
they exhibit wider distributions of Hb concentrations (34, 35) than
healthy patients. In this study, the accuracy of the biophysical
measurements has been enhanced by subdividing blood samples
from SCD patients into four densities and quantifying density-
dependent properties of individual RBCs. This density separation
additionally allows for decoupling Hb concentration from other
biophysical properties for individual RBCs. RBCs with shapes
that deviate the most from the normal biconcave shape tend to
occur in the denser populations (Fig. 2), populations that are
generally absent in healthy human blood. It has been suggested
that these cells have been irreversibly damaged either through the
normal aging process or from repeated cycles of oxygenation and
deoxygenation during blood circulation (36). In general, within
the first two fractions, most cells were discocytes, whereas frac-
tion III included discocytes and some elliptical and irreversibly
sickled cells. The highest number of elliptical and irreversibly
sickled cells was observed in fraction IV with fewer discocytes
present (Fig. 2).
Fig. 3 shows cell membrane fluctuations as a function of cell
density. The average amplitude of membrane fluctuations or
“flickering” is inversely proportional to the overall stiffness of
the cell, that is, softer cells show larger fluctuations. This trend is
consistent with previous findings on membrane fluctuations of
different types of RBCs (37). The overall stiffness of the cells
increases with an increase in the Hb concentration within the
cytosol. The increase in cell membrane stiffness can be extracted
from fluctuation amplitude data by recourse to theoretical
analysis (32, 38). Specifically, this analytical model links mem-
brane fluctuations to four biomechanical properties: in-plane
shear modulus (μ), bending stiffness (κ), and area expansion
modulus (KA) of the cell membrane, as well as the viscosity of the
cytosol (η). Within the range of RBC Hb concentrations in sickle
cell patients, microviscosity of the Hb solution can be linked to
the concentration of the Hb (39). Fractionation of the RBCs into
four density categories before the measurements enables us to
estimate the average viscosity value in each density fraction. Ad-
ditionally, the area expansion modulus of the cell membrane,
Fig. 1. Optical measurement of morphological properties of RBCs. Mor-
phological information about the sample (eccentricity, surface area, and
volume) can be obtained from deformations of the optical wave front after
its traversal through RBCs. The phase delay of the optical wave front after
passing through the sample is related to optical properties and morphology
of the sample, and can be accurately measured through advanced inter-
ferometry. Accurate measurements of the morphology over time reveal
thermal fluctuations that cause out-of-plane displacements of the cell
membrane (bottom right image), which provide insights into the bio-
mechanical properties of the whole cell (bending and shear modulus as well
the cytosol viscosity). (Scale bars: 4 μm.)
Fig. 2. Density fractionation of RBCs from sickle patients and healthy donors.
(A) Representative images of RBCs in each density fraction from blood sample of
a sickle patient. I, II, III, and IV represent density fractions that are 26.6, 30.2, 34.1,
and 37.8 g·dL−1, respectively. (B) Representative distribution of density volume
percentage in sickle cell patients both on and off drug as well as healthy donors.
RBCs of sickle patients, regardless of HU treatment, have denser fractions (III and
IV) that are absent from healthy blood. (Scale bar: 10 μm.)
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dominated by the properties of the lipid bilayer, has been well
characterized using micropipette measurements (40). Therefore,
viscosity of the cytosol and area expansion modulus of the cell
membrane corresponding to literature values are held constant
in our model for each density fraction. Thereafter, shear and
bending moduli have been extracted from a fit of the experi-
mental membrane fluctuations to the analytical model.
As seen in Fig. 3, there is a steady increase in the shear modulus
of the cell membrane as the cell density increases, whereas
bending modulus remains relatively constant for all density frac-
tions. It has been suggested (32, 38) that changes in shear modulus
can be attributed to the spectrin network supporting the cell
membrane, whereas bending properties are mainly a function of
the configuration of phospholipids, fatty acids, and cholesterols in
the RBC membrane. These results are consistent with previous
reports that the mechanical damage of RBCs is mainly caused by
the rearrangement of the membrane scaffold proteins rather than
a change in lipid bilayer or integral proteins (41, 42).
The topographic information obtained using this technique
could offer insights into our understanding of SCD pathophysi-
ology. Cellular volume and the ratio of surface area to volume of
the RBCs are two such important geometric markers. The surface
area-to-volume ratio in particular along with cytoplasmic viscosity
and membrane stiffness regulate deformability of red cells nec-
essary for oxygen delivery to tissues and organs (43, 44). They also
affect the deformability of RBCs, which becomes critical when
they pass through narrow capillaries. As seen in Fig. 3, average cell
volume decreases as cell density increases. This decrease in vol-
ume is accompanied by an increase in the surface area-to-volume
ratio. An additional geometric factor of potential relevance to the
pathophysiology of the RBCs is the eccentricity of the individual
cells. Formation of the polymerized HbS in the cytosol results in
forces on the cell membrane that could occur repeatedly as cells
experience cycles of oxygenation and deoxygenation. As seen in
Fig. 3, the eccentricity of the denser cells is significantly higher
than that of lower density cells. However, among less dense cells,
there is no statistically significant difference in eccentricity. This
suggests that denser RBCs in blood experience some irrevers-
ible changes in shape that are associated with changes in the skel-
etal or membrane proteins that regulate the biconcave shape of
normal RBCs.
Effects of HU Treatment on Cellular Biomarkers. To assess the effect
of HU on the biomechanical and morphological properties, we
examined RBCs from patients “on” and “off” HU treatment.
All measurements from such on-drug and off-drug populations
were grouped together for each density category, as shown in
Fig. 4, to illustrate the overall effect of drug treatment. For
almost all properties and all density categories, a statistically
significant difference was observed as a result of HU treatment.
Bending modulus of the cell membrane has been excluded from
this comparison because a specific trend was not observed for
individual patients as shown in Fig. 3.
These results show that RBCs under HU treatment are softer
on average regardless of their density. Shear modulus extracted
from membrane fluctuations using the analytical model shows a
corresponding decrease in the membrane rigidity for the on-drug
population. RBCs of patients under HU treatment exhibit a
higher volume and a smaller ratio of surface area to volume, on
average. There was no clear difference between average eccen-
tricity value for lighter sickle cells; however, denser cells did
exhibit a higher eccentricity ratio for patients off HU treatment.
Correlation of Biophysical Properties with Clinical Measurements.
There is a range of clinically measured parameters that pro-
vide insights into the pathways and effectiveness of HU therapy
for SCD patients. These laboratory parameters are broadly
derived from either cellular evaluation tests such as hematocrit
and mean corpuscular volume (MCV), or from the molecular
profile tests such as those involving blood composition using gel
Fig. 3. Biophysical response of the RBCs of sickle patients as a function of cell density. (A) Biomechanical properties of the RBCs as a function of cell density.
Each data point represents an individual RBC within the indicated fraction. The black horizontal line represents the mean value within the cell distribution.
(B) By measuring the 3D shape of RBCs, morphological properties of relevance have been plotted as a function of the cell density. To calculate eccentricity,
initially an ellipse is fitted to each RBC andminor axis (b) andmajor axis (a) of the ellipse are measured. The eccentricity ratio is then calculated as {1 − (a/b)2}1/2. The bar
graphs denote mean values, whereas error bars represent ±SD. The plotted data correspond to patient III as identified in Table S1. Standard two-tailed t tests were
used to determine the significance of the difference between two groups of data, where **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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electrophoresis. These parameters are listed in Supporting In-
formation for all patients in this study. Two well-known re-
sponses of HU treatment are the induction of HbF and increase
in MCV due to the ability of the drug to induce stress eryth-
ropoiesis (6, 24, 45, 46). To assess whether MCV and/or HbF
modulate differences in biophysical properties at normoxia, we
categorized the patient data into low- and high-MCV and low-
and high-HbF populations based on the median value for all
patients. Fig. 5 shows the morphological and biomechanical
properties of density-sorted red cells that have been grouped
based on the median MCV value for all patients, which is about
84 fL. As shown, a statistically significant difference is ob-
served for all properties except the cellular eccentricity ratio.
Surprisingly, separation of low- and high-HbF populations accord-
ing to the median HbF value for all patients did not reveal any
statistically significant differences in the biophysical properties, as
seen in Fig. 6.
Discussion
Although various techniques can be used for the measurement of
biomechanical properties of biological cells (47), quantitative
interferometric techniques are unique in that they are capable of
providing 3D morphological information and biomechanical
properties simultaneously for individual RBCs in a minimally in-
vasive way. This unique feature, along with the high-throughput
nature of the technique, allows for measuring hundreds of cells
from sickle patients in a short period (that is, a few minutes). Al-
though interferometric optical techniques have been used in prior
studies of RBCs from sickle patients (37, 48), they were limited to
the RBCs from single patients and variations of Hb concentrations
in individual RBCs were not accounted for. Taking such density
variations into account significantly alters the inferences derived
from optical measurements because RBCs from sickle patients are
known to have a wider distribution of the Hb concentrations in the
cytosol than those from healthy patients (34, 35) (Fig. 2). Den-
sity fractionation of RBCs of sickle patients in this work resulted
in two major improvements. First, as outlined in Methods, having
Hb concentration for a subpopulation of RBCs allows for more
precise measurements of the optically measured biophysical
properties. Additionally, by measuring the cytosol viscosity using
Hb density, overall changes in cell deformability can be inter-
preted more thoroughly.
HU treatment has been shown to reduce RBC sickling and the
incidence of vasoocclusive crises in SCD patients. The mecha-
nism through which HU brings about these benefits is, however,
not well established. The antisickling benefit is believed to be
mainly due to the induction of the HbF (45). Another widely
known effect of the drug has been an increase in mean cell
volume of RBCs (49). Strong correlation of the biophysical
properties of individual RBCs with the MCV value (Fig. 5),
rather than HbF (Fig. 6), suggests that the static biophysical
effects of higher MCV may be the dominant drug effect at
normoxia. It is, therefore, possible that the effect of HbF in-
duction is more prominent at hypoxia, because its principal
biochemical effect is to inhibit hypoxia-induced HbS polymeri-
zation. Multiple studies indeed show that, in hypoxic conditions,
the effect of the HbF level correlates with the kinetic biophysi-
cal properties (29, 30, 50). These same studies do not show any
drug effect for properties such as blood rheology measured at
normoxic condition. The HbF content of the cells, however, is
known to have more of a dominant effect on the inhibition of the
sickling events. Our biomechanical and morphological mea-
surements reveal differences between on-drug and off-drug pa-
tient populations as well as classification based on the MCV
value at normoxia. One possible explanation is that static bio-
physical properties reported in this study reflect a combination of
changes that RBCs experienced during the blood circulation.
The degree and frequency of cell sickling as well as the damage
to the cell membrane due to large deformations in the capillaries
may all have an effect on the red cell biomechanics and mor-
phology even at normoxia. Even the antisickling effects of HU
treatment may not be rationalized by HbF induction alone (51, 52).
Fig. 4. Biophysical properties of individual RBCs for “on” and “off” HU drug patients. (A) Biomechanical properties as a function of four different cell
densities. (B) Morphological parameters as a function of cell density. The number of measurements per patient for each density categories varies between 20
and 25 incidents. The exact numbers for each measurement are as follows: Non = 126, 136, 136, and 128, and Noff = 172, 187, 164, and 165, for density I, II, III,
and IV, respectively. The height of bar graph in each case represents the mean value, whereas the vertical error bars represent ±SD. Standard two-tailed t tests
were used to determine the significance of the difference between two groups of data, where *P < 0.05, ***P < 0.001, and “ns” indicates P > 0.05.
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Therefore, our results along with recent studies suggest that the
beneficial effect of HU treatment is partially through modulation of
cellular biophysical properties. However, quantifying the precise
contribution of these biophysical properties relative to increased
HbF at the cellular level requires further development of more
advanced techniques capable of measuring cellular HbF content.
Methods
Sample Preparation. Blood samples were collected under an Excess Human
Material Protocol approved by the Partners Healthcare Institutional Review
Board with a waiver of consent. All samples were stored at 4 °C during the
shipping and storage and used within 3 d of blood harvest. Healthy whole
blood was obtained from Research Blood Components. Fractionation of sickle
and healthy RBCs was performed as described here in more detail (50). Briefly,
OptiPrep Density Gradient Medium (Sigma-Aldrich) was used to create a
stepwise gradient to separate RBCs by cell density. Using Dulbecco’s PBS
(HyClone DPBS; Thermo Scientific) to adjust the density of the OptiPrep me-
dium, densities of 1.081, 1.091, 1.1, and 1.111 g/mL were made and layered in
2.5-mL volumes in order of increasing density with the densest layer on the
bottom. Following two washes with PBS (HyClone; Thermo Scientific) and
centrifugation at 821 × g at 21 °C for 5 min, cell samples were suspended in PBS
to achieve a 70–80% hematocrit. Fully suspended cell suspensions were layered
on the least dense layer and centrifuged at 821 × g for 30 min at 21 °C. Cell
populations fractionated between gradient layers were isolated carefully. A
population pelleted after the centrifugation was also isolated. Fractions had
average densities of 1.086 ± 0.005 g/mL (density 1), 1.095 ± 0.005 g/mL (density
2), 1.105 ± 0.005 g/mL (density 3), and >1.111 g/mL (density 4). Following two
washes with PBS for removal of gradient medium, fractionated cells were
suspended in PBS with 1% BSA (Sigma-Aldrich) where 1 μL of pellet was sus-
pended in 200 μL of PBS–BSA and kept at 4 °C until use.
Optical Measurements. Quantitative phase imaging (QPI) is a technique for
accurately measuring the structure and function of biological samples without
requiring exogenous contrast agents (53, 54). QPI is based on the principles of
interferometry and measures the phase delay of the optical wave front
passing through the biological samples. In simple terms, the measured phase
Δϕ is a function of RI contrast and sample height: Δϕðx, y, tÞ= 2πΔnhðx, y, tÞ=λ,
where Δn=nc −nm, and nc and nm are the average RIs of the cell and the
culture medium, respectively. hðx, yÞ is the cell height, and λ is the wave-
length of light. In these experiments, we used λ = 589 nm and the imaging
speed was 125 fps. The optical phase delay contains information on both
optical properties as well as morphology of the biological samples. Diffrac-
tion phase microscope (DPM) is one such instrument that has both the
common-path and off-axis features of an interferometer (31). Common-path
phase microscopy entails samples and reference beams side-by-side to en-
sure minimal system phase noise required for measuring nanometer motions
of biological samples, whereas off-axis interferometry is used to acquire
single-shot interferograms beneficial for studying fast dynamics of biological
systems. In the context of RBCs, these two features make DPM an excellent
candidate for measuring rapid thermal fluctuations of the red cell mem-
brane. It must be noted that RI of the Hb is related to the concentration of
the Hb and could be calculated as follows: nc = nw(1 + βc), where nw is the RI
of water, c is the concentration of the Hb, and β is the wavelength-de-
pendent RI increment (55). Using the Hb concentration, the average RI has
been calculated for each density category to provide a more accurate ac-
count of the red cell morphology.
Mechanical Modeling. It was first shown by Brochard and Lennon (56) that the
decay rate of the thermal fluctuations of a flat lipid bilayer can be linked to the
mechanical properties of the membrane. Their model was later modified to
account for the geometry of the RBCs and contribution of the spectrin network
beneath the lipid bilayer, the details of which can be found elsewhere (32, 38).
In short, in the improved methodology, RBCs are modeled as a composite
Fig. 6. Biophysical properties of RBCs of SCD pa-
tients grouped based on HbF percentage. “Low” and
“High” in these figures represent HbF values rela-
tive to the median for all patients, which is 8.5%.
(A) Biomechanical properties as a function of the cell
density and HbF level. (B) Morphological parameters
as a function of the cell density and HbF level. Dots
represent mean values for individual patients. There
is no statistically significant difference between pa-
tients with low and high clinically measured HbF
levels. Standard two-tailed t tests were used to de-
termine the significance of the difference between
two groups of data, where “ns” indicates P > 0.05.
Fig. 5. Biophysical properties of RBCs of SCD pa-
tients grouped based on the MCV value of the RBCs.
“Low” and “High” in these figures represent MCV
values relative to the median MCV value for all pa-
tients, which is 84 fL. (A) Biomechanical properties
as a function of the cell density and MCV value.
(B) Morphological parameters as a function of the
cell density and MCV value. Dots represent mean
values for individual patients. Low MCV and high
MCV are defined as the values that are less and more
than the median value, respectively. The data points
in each case represent the mean value, whereas the
vertical error bars represent ±SD. Standard two-
tailed t tests were used to determine the significance
of the difference between two groups of data,
where *P < 0.05, **P < 0.01, ***P < 0.001, and “ns”
indicates P > 0.05.
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membrane surrounded by viscous fluids inside and outside the membrane
surface. Using the experimental spatiotemporal fluctuations of the cell
membrane, one can calculate the out-of-plane correlation function of the
membrane at various frequencies. Thereafter, from a comparison of the
theoretical prediction of the model and experimental results, one can fit
for key biomechanical properties, namely, shear modulus (μ), bending
stiffness (κ), and area expansion modulus (KA) of the cell membrane, as well
as the viscosity of the cytosol (η). At low frequencies, cell membrane re-
sponse is dominated by the elastic properties of the cell membrane and
does not vary with the chosen frequency at which mechanical parameters
are calculated (32). All parameters reported in this paper have been cal-
culated at ω = 10 rad/s. Average viscosity of each subpopulation can be
calculated from the relationship between microviscosity and concentration
of the Hb in the cytosol (39). Micropipette measurements show the area
expansion modulus of the membrane (KA = μ + λ) of the RBC is orders of
magnitude higher than the shear modulus (λ » μ). The values of cytosol viscosity
(η) and area expansion modulus (KA) therefore have been fed into the model,
and bending modulus (κ) and shear modulus (μ) have been extracted from a fit
between the experimental measurement of the membrane fluctuations and
prediction of the analytical model.
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